Proxygen GmbH

PROXYGEN

Pharmaceutical and therapeutic preparations for the treatment of cancer, immunological diseases, inflammatory diseases, neurological diseases, and genetic disorders; pharmaceutical and therapeutic preparations for modulating protein degradation pathways;Chemical preparations for scientific purposes; molecules for use in industry, namely, protein-modulating molecules for use in the pharmaceutical industry; molecules for use in science, namely, protein-modulating molecules for use in the pharmaceutical industry; molecules for molecular biology, other than for medical or veterinary use, namely, protein-modulating molecules for use in the pharmaceutical industry;Scientific research and development services; scientific research of protein degradation; discovery and development of protein degradation pathway modulating molecules, namely, scientific research services; scientific research of protein ubiquitination; discovery and development of proximity-inducing agents, namely, scientific research services; research and development of proteolysis targeting chimeras; research and development of ligase-mediated protein modifications; discovery and development of molecular glue degraders, namely, scientific research services; discovery and development of monovalent protein degraders, namely, scientific research services;